Literature DB >> 21156967

Effects of artesunate on cytokinesis and G₂/M cell cycle progression of tumour cells and budding yeast.

Lisa Steinbrück1, Gislene Pereira, Thomas Efferth.   

Abstract

Artesunate, a semi-synthetic derivative of artemisinin, is an effective and safe anti-malaria drug, which also exhibits activity towards cancer cells. The present investigation studied the effect of artesunate on the mitosis of cancer and yeast cells by fluorescence microscopy and mRNA microarrays with a focus on the mitotic spindle checkpoint. The cytotoxicity of artesunate towards seven cell lines from six different cancer types was determined using the XTT assay. Furthermore, the cell cycle distribution of artesunate-treated cells was investigated by flow cytometry and immunofluorescence. To elucidate the genes mediating the effect of artesunate in the mitotic spindle checkpoint, knockout mutants of Saccharomyces cerevisiae were generated, since yeast knockouts are easier to generate than knockout strains of mammalian cells. Four out of the seven tested cell lines showed a G₂/M arrest upon artesunate exposure. Cells residing in the G₂/M arrest revealed multiple centrosomes, small multiple spindles and multi-nucleated cells, suggesting a defect in cytokinesis. The mitotic spindle checkpoint genes bub1, bub2, bub3, mad1, mad2 and mad3 were individually deleted and the sensitivity of these mutants towards artesunate was determined by monitoring the cell growth. The Δbub3 and Δmad3 mutants showed an increased sensitivity and the Δmad2 mutant a slightly decreased sensitivity to artesunate in comparison to the respective wild type. Bub3, Mad3 and Mad2 are the main regulators of the mitotic spindle checkpoint, suggesting that artesunate may interfere with this control mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156967

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  17 in total

Review 1.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

2.  Evaluation of artemisinins for the treatment of acute myeloid leukemia.

Authors:  Christina D Drenberg; Jassada Buaboonnam; Shelley J Orwick; Shuiying Hu; Lie Li; Yiping Fan; Anang A Shelat; R Kiplin Guy; Jeffrey Rubnitz; Sharyn D Baker
Journal:  Cancer Chemother Pharmacol       Date:  2016-04-28       Impact factor: 3.333

3.  Artesunate-induced Cellular Effects Are Mediated by Specific EPH Receptors and Ephrin Ligands in Breast Carcinoma Cells.

Authors:  Tanin Zadeh; Mariana Lucero; Raj P Kandpal
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

4.  Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line.

Authors:  Liang Liu; Lian Fu Zuo; Jian Wen Guo
Journal:  Oncol Lett       Date:  2013-08-23       Impact factor: 2.967

5.  Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua.

Authors:  Elmar Breuer; Thomas Efferth
Journal:  Nat Prod Bioprospect       Date:  2014-04-12

6.  Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.

Authors:  Da Eun Jeong; Hye Jin Jin Song; Sharon Lim; Se Jeong Jeong Lee; Joung Eun Lim; Do-Hyun Nam; Kyeung Min Joo; Byong Chang Jeong; Seong Soo Jeon; Han Yong Choi; Hye Won Lee
Journal:  Oncotarget       Date:  2015-10-20

7.  The Effects of Artemisinin on the Cytolytic Activity of Natural Killer (NK) Cells.

Authors:  Youn Kyung Houh; Kyung Eun Kim; Sunyoung Park; Dae Young Hur; Seonghan Kim; Daejin Kim; Sa Ik Bang; Yoolhee Yang; Hyun Jeong Park; Daeho Cho
Journal:  Int J Mol Sci       Date:  2017-07-24       Impact factor: 5.923

8.  Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo.

Authors:  Benjamin Krusche; Joachim Arend; Thomas Efferth
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-08       Impact factor: 2.629

9.  Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein.

Authors:  Xiaoguang Li; Qian Ba; Yanling Liu; Qingxi Yue; Peizhan Chen; Jingquan Li; Haibing Zhang; Hao Ying; Qiurong Ding; Haiyun Song; Hong Liu; Ruiwen Zhang; Hui Wang
Journal:  Cell Discov       Date:  2017-11-21       Impact factor: 10.849

10.  Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia.

Authors:  Dominique R Perez; Yelena Smagley; Matthew Garcia; Mark B Carter; Annette Evangelisti; Ksenia Matlawska-Wasowska; Stuart S Winter; Larry A Sklar; Alexandre Chigaev
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.